nach oben

Erschienen in:

03.02.2023 | Gynecologic Oncology

Management of patients with advanced epithelial ovarian cancer: a European survey

verfasst von: Floriane Jochum, Martina Aida Angeles, Vincent Balaya, Leonor Drouin, Tanja Nikolova, Patrice Mathevet, Fabrice Lécuru, Henri Azais, Sarah Betrian, Pierre-Adrien Bolze, Yohann Dabi, Yohan Kerbage, Claire Sanson, François Zaccarini, Fréderic Guyon, Cherif Akladios, Arthur Hsu, Sofiane Bendifallah, Elise Deluche, Benedetta Guani

Erschienen in: Archives of Gynecology and Obstetrics | Ausgabe 2/2023

Einloggen, um Zugang zu erhalten

Abstract

Background

The aim of this study was to assess current European practices in the management of patients with advanced epithelial ovarian cancer in 2021.

Methods

A 58-question electronic survey was distributed anonymously to the members of six European learned societies. Initial diagnostic workup and staging, pathological data, surgical data, treatments and follow-up strategies were assessed.

Results

A total of 171 participants from 17 European countries responded to emailed surveys. Most participants were experienced practitioners (superior than 15 years of experience) specializing in gynecology-obstetrics (29.8%), surgical oncology (25.1%), and oncogynecology (21.6%). According to most (64.8%) participants, less than 50% of patients were eligible for primary debulking surgery. Variations in the rate of primary debulking surgery depending on the country of origin of the practitioners were observed in this study. The LION study criteria were applied in 70.4% of cases during PDS and 27.1% after chemotherapy. In cases of BRCA1-2 mutations, olaparib was given by 75.0–84.8% of respondents, whereas niraparib was given in cases of BRCA wild-type diseases.

Conclusions

This study sheds light on current practices and attitudes regarding the management of patients with advanced epithelial ovarian cancer in Europe in 2021.

Nur mit Berechtigung zugänglich

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68:394–424. https://doi.org/10.3322/caac.21492CrossRefPubMed

Pavlidis N, Rassy E, Vermorken JB, Assi T, Kattan J, Boussios S, Smith-Gagen J (2021) The outcome of patients with serous papillary peritoneal cancer, fallopian tube cancer, and epithelial ovarian cancer by treatment Eras: 27 years data from the SEER registry. Cancer Epidemiol 75:102045CrossRefPubMed

Colombo N, Sessa C, du Bois A, Ledermann J, McCluggage WG, McNeish I, Morice P, Pignata S, Ray-Coquard I, Vergote I et al (2019) ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease†. Ann Oncol 30:672–705. https://doi.org/10.1093/annonc/mdz062CrossRefPubMed

Chi DS, Eisenhauer EL, Zivanovic O, Sonoda Y, Abu-Rustum NR, Levine DA, Guile MW, Bristow RE, Aghajanian C, Barakat RR (2009) Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol Oncol 114:26–31. https://doi.org/10.1016/j.ygyno.2009.03.018CrossRefPubMed

Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ (2002) Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20:1248–1259. https://doi.org/10.1200/JCO.2002.20.5.1248CrossRefPubMed

Moschetta M, Boussios S, Rassy E, Samartzis EP, Funingana G, Uccello M (2020) Neoadjuvant treatment for newly diagnosed advanced ovarian cancer: where do we stand and where are we going? Ann Transl Med 8:1710CrossRefPubMedPubMedCentral

van Driel WJ, Koole SN, Sikorska K, Schagen van Leeuwen JH, Schreuder HWR, Hermans RHM, de Hingh IHJT, van der Velden J, Arts HJ, Massuger LFAG et al (2018) Hyperthermic intraperitoneal chemotherapy in ovarian cancer. New England J Med 378:230–240. https://doi.org/10.1056/NEJMoa1708618CrossRef

Fagotti A, Ferrandina MG, Vizzielli G, Pasciuto T, Fanfani F, Gallotta V, Margariti PA, Chiantera V, Costantini B, Alletti SG et al (2020) Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850). Int J Gynecol Cancer. https://doi.org/10.1136/ijgc-2020-001640

Colombo N, Ledermann JA, ESMO Guidelines Committee (2021) Electronic address: clinicalguidelines@esmo.org updated treatment recommendations for newly diagnosed epithelial ovarian carcinoma from the ESMO clinical practice guidelines. Ann Oncol 32:1300–1303. https://doi.org/10.1016/j.annonc.2021.07.004CrossRefPubMed

10.

Norell CH, Butler J, Farrell R, Altman A, Bentley J, Cabasag CJ, Cohen PA, Fegan S, Fung-Kee-Fung M, Gourley C et al (2020) Exploring international differences in ovarian cancer treatment: a comparison of clinical practice guidelines and patterns of care. Int J Gynecol Cancer 30:1748–1756. https://doi.org/10.1136/ijgc-2020-001403CrossRefPubMedPubMedCentral

11.

Drouin L, Guani B, Balaya V, Azaïs H, Betrian S, Bolze P-A, Dabi Y, Kerbage Y, Sanson C, Zaccarini F et al (2021) Results of a 2021 french national survey on management of patients with advanced stage epithelial ovarian cancer. J Clin Med 10:4829. https://doi.org/10.3390/jcm10214829CrossRefPubMedPubMedCentral

12.

Lavoue V, Huchon C, Akladios C, Alfonsi P, Bakrin N, Ballester M, Bendifallah S, Bolze P-A, Bonnet F, Bourgin C et al (2019) Management of epithelial ovarian cancer. Short text drafted from the French joint recommendations of FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY and endorsed by INCa. Bull Cancer 106:354–370. https://doi.org/10.1016/j.bulcan.2019.01.014CrossRefPubMed

13.

Fotopoulou C, Hall M, Cruickshank D, Gabra H, Ganesan R, Hughes C, Kehoe S, Ledermann J, Morrison J, Naik R et al (2017) British Gynaecological cancer society (BGCS) epithelial ovarian/fallopian tube/primary peritoneal cancer guidelines: recommendations for practice. Eur J Obstet Gynecol Reprod Biol 213:123–139. https://doi.org/10.1016/j.ejogrb.2017.04.016CrossRefPubMed

14.

Hall JP, Chang J, Moon R, Higson O, Byrne K, Doherty JP, Cappelleri JC (2020) Real-world treatment patterns in patients with advanced (Stage III–IV) ovarian cancer in the USA and Europe. Future Oncol. https://doi.org/10.2217/fon-2020-0083CrossRefPubMed

15.

Audibert C, Perlaky A, Stuntz M, Glass D (2017) Variability in the therapeutic management of advanced ovarian cancer patients: a five-country survey of oncologists. Drug Des Devel Ther 11:3471–3479. https://doi.org/10.2147/DDDT.S151420CrossRefPubMedPubMedCentral

16.

Fagotti A, Ferrandina MG, Vizzielli G, Pasciuto T, Fanfani F, Gallotta V, Margariti PA, Chiantera V, Costantini B, Gueli Alletti S et al (2020) Randomized trial of primary debulking surgery versus neoadjuvant chemotherapy for advanced epithelial ovarian cancer (SCORPION-NCT01461850). Int J Gynecol Cancer 30:1657–1664. https://doi.org/10.1136/ijgc-2020-001640CrossRefPubMed

17.

Vergote I, Amant F, Ehlen T (2010) Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. The New Engl J Med. https://doi.org/10.1056/NEJMoa0908806CrossRefPubMed

18.

Kehoe S, Hook J, Nankivell M, Jayson GC, Kitchener H, Lopes T, Luesley D, Perren T, Bannoo S, Mascarenhas M et al (2015) Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled. Non-Inferiority Trial Lancet 386:249–257. https://doi.org/10.1016/S0140-6736(14)62223-6CrossRefPubMed

19.

Coleridge SL, Bryant A, Lyons TJ, Goodall RJ, Kehoe S, Morrison J (2019) Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD005343.pub4CrossRefPubMedPubMedCentral

20.

Vergote I, Coens C, Nankivell M, Kristensen GB, Parmar MKB, Ehlen T, Jayson GC, Johnson N, Swart AM, Verheijen R et al (2018) Neoadjuvant chemotherapy versus debulking surgery in advanced tubo-ovarian cancers: pooled analysis of individual patient data from the EORTC 55971 and CHORUS trials. Lancet Oncol 19:1680–1687. https://doi.org/10.1016/S1470-2045(18)30566-7CrossRefPubMed

21.

Chéreau E, Ballester M, Selle F, Cortez A, Daraï E, Rouzier R (2010) Comparison of peritoneal carcinomatosis scoring methods in predicting resectability and prognosis in advanced ovarian cancer. Am J Obstet Gynecol 202(178):e1-178.e10. https://doi.org/10.1016/j.ajog.2009.10.856CrossRef

22.

Chi DS, Eisenhauer EL, Lang J, Huh J, Haddad L, Abu-Rustum NR, Sonoda Y, Levine DA, Hensley M, Barakat RR (2006) What is the optimal goal of primary cytoreductive surgery for bulky stage iiic epithelial ovarian carcinoma (EOC)? Gynecol Oncol 103:559–564. https://doi.org/10.1016/j.ygyno.2006.03.051CrossRefPubMed

23.

Lyons YA, Reyes HD, McDonald ME, Newtson A, Devor E, Bender DP, Goodheart MJ, Gonzalez Bosquet J (2020) Interval debulking surgery is not worth the wait: a national cancer database study comparing primary cytoreductive surgery versus neoadjuvant chemotherapy. Int J Gynecol Cancer 30:845–852. https://doi.org/10.1136/ijgc-2019-001124CrossRefPubMedPubMedCentral

24.

Moore K, Colombo N, Scambia G, Kim B-G, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS et al (2018) Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 379:2495–2505. https://doi.org/10.1056/NEJMoa1810858CrossRefPubMed

25.

Delga B, Classe J-M, Houvenaeghel G, Blache G, Sabiani L, El Hajj H, Andrieux N, Lambaudie E (2020) 30 years of experience in the management of stage iii and iv epithelial ovarian cancer: impact of surgical strategies on survival. Cancers (Basel) 12:768. https://doi.org/10.3390/cancers12030768CrossRefPubMed

26.

González-Martín A, Pothuri B, Vergote I, DePont Christensen R, Graybill W, Mirza MR, McCormick C, Lorusso D, Hoskins P, Freyer G et al (2019) Niraparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 381:2391–2402. https://doi.org/10.1056/NEJMoa1910962CrossRefPubMed

27.

Ray-Coquard I, Pautier P, Pignata S, Pérol D, González-Martín A, Berger R, Fujiwara K, Vergote I, Colombo N, Mäenpää J et al (2019) Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med 381:2416–2428. https://doi.org/10.1056/NEJMoa1911361CrossRefPubMed

28.

Alejandra M, Gertych W, Pomel C, Ferron G, Lusque A, Angeles MA, Lambaudie E, Rouzier R, Bakrin N, Golfier F et al (2021) Adherence to French and ESGO quality indicators in ovarian cancer surgery: an ad-hoc analysis from the prospective multicentric CURSOC study. Cancers (Basel) 13:1593. https://doi.org/10.3390/cancers13071593CrossRefPubMed

29.

Akladios C, Daraï É, Golfier F, Lecuru F, Collinet P, Uzan C, Lavoué V, Guyon F, Ferron G, Querleu D (2021) Certification nationale pour la chirurgie des cancers gynécologiques. Bull Cancer 108:806–812. https://doi.org/10.1016/j.bulcan.2021.03.019CrossRefPubMed

30.

Querleu D, Planchamp F, Chiva L, Fotopoulou C, Barton D, Cibula D, Aletti G, Carinelli S, Creutzberg C, Davidson B et al (2016) European society of gynaecologic oncology quality indicators for advanced ovarian cancer surgery. Int J Gynecol Cancer 26:1354–1363. https://doi.org/10.1097/IGC.0000000000000767CrossRefPubMed

31.

Ferrero A, Ditto A, Giorda G, Gadducci A, Greggi S, Daniele A, Fuso L, Panuccio E, Scaffa C, Raspagliesi F et al (2014) Secondary cytoreductive surgery for isolated lymph node recurrence of epithelial ovarian cancer: a multicenter study. Eur J Surg Oncol 40:891–898. https://doi.org/10.1016/j.ejso.2013.11.026CrossRefPubMed

32.

du Bois A, Reuss A, Harter P, Pujade-Lauraine E, Ray-Coquard I, Pfisterer J (2010) Arbeitsgemeinschaft gynaekologische onkologie studiengruppe ovarialkarzinom; groupe d’investigateurs nationaux pour l’etude des cancers ovariens potential role of lymphadenectomy in advanced ovarian cancer: a combined exploratory analysis of three prospectively randomized phase III multicenter trials. J Clin Oncol 28:1733–1739. https://doi.org/10.1200/JCO.2009.25.3617CrossRefPubMed

33.

Zhou J, Shan G, Chen Y (2016) The effect of lymphadenectomy on survival and recurrence in patients with ovarian cancer: a systematic review and meta-analysis. Jpn J Clin Oncol 46:718–726. https://doi.org/10.1093/jjco/hyw068CrossRefPubMed

34.

Panici PB, Maggioni A, Hacker N, Landoni F, Ackermann S, Campagnutta E, Tamussino K, Winter R, Pellegrino A, Greggi S et al (2005) Systematic aortic and pelvic lymphadenectomy versus resection of bulky nodes only in optimally debulked advanced ovarian cancer: a randomized clinical trial. J Natl Cancer Inst 97:560–566. https://doi.org/10.1093/jnci/dji102CrossRefPubMed

35.

Harter P, Sehouli J, Lorusso D, Reuss A, Vergote I, Marth C, Kim J-W, Raspagliesi F, Lampe B, Aletti G et al (2019) A randomized trial of lymphadenectomy in patients with advanced ovarian neoplasms. N Engl J Med 380:822–832. https://doi.org/10.1056/NEJMoa1808424CrossRefPubMed

36.

Morgan RJ, Alvarez RD, Armstrong DK, Burger RA, Chen LM, Copeland L;, et al (2013) NCCN clinical practice guidelines in oncology (NCCN Guidelines). Ovarian Cancer Incl Fallopian Tube Cancer Prim Peritoneal Cancer. 11:1199–1209

37.

Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Kurzeder C et al (2011) A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 365:2484–2496. https://doi.org/10.1056/NEJMoa1103799CrossRefPubMed

38.

Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, Mannel RS, Homesley HD, Fowler J, Greer BE et al (2011) Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 365:2473–2483. https://doi.org/10.1056/NEJMoa1104390CrossRefPubMed

39.

Ghose A, Gullapalli SVN, Chohan N, Bolina A, Moschetta M, Rassy E, Boussios S (2022) Applications of proteomics in ovarian cancer: dawn of a new era. Proteomes 10:16CrossRefPubMedPubMedCentral

40.

Hardesty MM, Krivak T, Wright GS, Hamilton E, Fleming EL, Gupta D, Keeton E, Chen J, Clements A, Gray HJ et al (2020) Phase II OVARIO study of niraparib + bevacizumab therapy in advanced ovarian cancer following front-line platinum-based chemotherapy with bevacizumab. Gynecol Oncol 159:3–4. https://doi.org/10.1016/j.ygyno.2020.06.006CrossRef

41.

Shah S, Cheung A, Kutka M, Sheriff M, Boussios S (2022) Epithelial ovarian cancer: providing evidence of predisposition genes. Int J Environ Res Public Health 19:8113CrossRefPubMedPubMedCentral

42.

Pujol P, Barberis M, Beer P, Friedman E, Piulats JM, Capoluongo ED, Garcia Foncillas J, Ray-Coquard I, Penault-Llorca F, Foulkes WD et al (2021) Clinical practice guidelines for BRCA1 and BRCA2 genetic testing. Eur J Cancer 146:30–47. https://doi.org/10.1016/j.ejca.2020.12.023CrossRefPubMed

43.

Tutt ANJ, Garber JE, Kaufman B, Viale G, Fumagalli D, Rastogi P, Gelber RD, de Azambuja E, Fielding A, Balmaña J et al (2021) Adjuvant olaparib for patients with BRCA1- or BRCA2-mutated breast cancer. N Engl J Med 384:2394–2405. https://doi.org/10.1056/NEJMoa2105215CrossRefPubMedPubMedCentral

44.

Boussios S, Rassy E, Shah S, Ioannidou E, Sheriff M, Pavlidis N (2021) Aberrations of DNA repair pathways in prostate cancer: a cornerstone of precision oncology. Expert Opin Ther Targets 25:329–333CrossRefPubMed

Titel: Management of patients with advanced epithelial ovarian cancer: a European survey
verfasst von: Floriane Jochum
Martina Aida Angeles
Vincent Balaya
Leonor Drouin
Tanja Nikolova
Patrice Mathevet
Fabrice Lécuru
Henri Azais
Sarah Betrian
Pierre-Adrien Bolze
Yohann Dabi
Yohan Kerbage
Claire Sanson
François Zaccarini
Fréderic Guyon
Cherif Akladios
Arthur Hsu
Sofiane Bendifallah
Elise Deluche
Benedetta Guani
Publikationsdatum: 03.02.2023
Verlag: Springer Berlin Heidelberg
Erschienen in: Archives of Gynecology and Obstetrics / Ausgabe 2/2023
Print ISSN: 0932-0067
Elektronische ISSN: 1432-0711
DOI: https://doi.org/10.1007/s00404-023-06948-3

Neu im Fachgebiet Gynäkologie und Geburtshilfe

Alter der Mutter beeinflusst Risiko für kongenitale Anomalie

28.05.2024 Kinder- und Jugendgynäkologie Nachrichten

Welchen Einfluss das Alter ihrer Mutter auf das Risiko hat, dass Kinder mit nicht chromosomal bedingter Malformation zur Welt kommen, hat eine ungarische Studie untersucht. Sie zeigt: Nicht nur fortgeschrittenes Alter ist riskant.

Fehlerkultur in der Medizin – Offenheit zählt!

28.05.2024 Fehlerkultur Podcast

Darüber reden und aus Fehlern lernen, sollte das Motto in der Medizin lauten. Und zwar nicht nur im Sinne der Patientensicherheit. Eine negative Fehlerkultur kann auch die Behandelnden ernsthaft krank machen, warnt Prof. Dr. Reinhard Strametz. Ein Plädoyer und ein Leitfaden für den offenen Umgang mit kritischen Ereignissen in Medizin und Pflege.

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

26.05.2024 Mammakarzinom Nachrichten

Frauen, die zum Zeitpunkt der Brustkrebsdiagnose eine hohe mammografische Brustdichte aufweisen, haben ein erhöhtes Risiko für ein baldiges Rezidiv, legen neue Daten nahe.

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Management of patients with advanced epithelial ovarian cancer: a European survey